Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer

Journal of Neuro-Oncology

Volumn 109, Issue 2, 2012, Pages 229-238

  Huang, Jun ^b   Li, Yan Michael ^a   Massague, Joan ^c   Sicheneder, Andy ^d   Vallera, Daniel A ^d   Hall, Walter A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Convection enhanced delivery; Immunotoxin; Metastatic brain tumors; Non small cell lung cancer; Targeted therapy; Xenograft model

Indexed keywords

ANTINEOPLASTIC AGENT; DIPHTHERIA TOXIN; DTAT; DTATEGF; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BRAIN METASTASIS; BRAIN TISSUE; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG INFUSION; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; REPORTER GENE; SURVIVAL TIME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHTHERIA TOXIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866021530     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0904-6     Document Type: Article

References (48)

1. Kaal EC, Niel CG, Vecht CJ (2005) Therapeutic management of brain metastasis. Lancet Neurol 4(5):289-298. doi:101016/S1474-4422 (05) 70072-7 (Pubitemid 40545040)
2. Delattre JY, Krol G, Thaler HT, Posner JB (1988) Distribution of brain metastases. Arch Neurol 45(7):741-744
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics 2008. CA Cancer J Clin 58(2):71-96. doi:10.3322/CA.2007.0010 (Pubitemid 351521864)
4. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745-751 (Pubitemid 27181303)
5. Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 96(1):115-142. doi:10.1007/s11060-009-0058-3
6. Shaw E, Scott C, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M (2003) RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 21(12):2364-2371. doi:10.1200/JCO.2003. 08.116 (Pubitemid 46621875)
7. Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, Tondat F, Inghirami G, Sapino A, Scagliotti GV, Papotti M, Novello S (2009) Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol 4(6):684-688. doi:10.1097/JTO.0b013e3181a 52359
8. Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY, Cardot N, Thyss A, Pedeutour F (2006) Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 17(6):981-985. doi:10.1093/annonc/mdl038 (Pubitemid 43778990)
9. Torp SH, Helseth E, Ryan L, Stolan S, Dalen A, Unsgaard G (1992) Expression of the epidermal growth factor receptor gene in human brain metastases. APMIS 100(8):713-719
10. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC (2009) Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 4(10):1212-1220. doi:10.1097/JTO. 0b013e3181b44321
11. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65(3):351-354. doi:10.1016/j.lungcan. 2008.12.011
12. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27(31):5255-5261. doi:10.1200/JCO.2009.22.0616
13. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS (2007) Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6(2):471-483. doi:10.1158/1535-7163. MCT-06-0416 (Pubitemid 46332449)
14. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD, Wistuba II (2009) HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15(15):4829-4837. doi:10.1158/1078-0432. CCR-08-2921
15. Wakelee H (2008) Antibodies to vascular endothelial growth factor in non-small cell lung cancer. J Thorac Oncol 3(6 Suppl 2):S113-S118. doi:10.1097/JTO.0b013e318174e993 (Pubitemid 351786740)
16. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D (2007) Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl):277S-289S. doi:10.1378/chest.07-1381
17. Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gurpide A, de Castro J, Polo E, Puig T, Taron M, Colomer R, Rosell R (2011) Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 37(3):624-631. doi:10.1183/09031936.00195609
18. Ricciardi S, Tomao S, de Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10(1):28-35. doi:10.3816/CLC.2009.n. 004
19. Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS (2010) Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem 285(35):26878-26888. doi:10.1074/jbc. M109.077677
20. Shih CM, Kuo WH, Lin CW, Chen W, Cheng WE, Chen SC, Lee YL (2011) Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer. Clin Chim Acta 412(1-2):194-198. doi:10.1016/j.cca.2010.10.004
21. Jacobsen B, Ploug M (2008) The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 15(25):2559-2573
22. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6(7):559-565. doi:10.1038/nrc1891 (Pubitemid 43980544)
23. Hall WA (1996) Immunotoxin therapy. Neurosurg Clin N Am 7(3):537-546 (Pubitemid 26246636)
24. Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA (2011) A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol 103(2):255-266. doi:10.1007/s11060-010-0392-5
25. Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA (2009) A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res 15(19):6137-6147. doi:10.1158/1078-0432. CCR-09-0696
26. Hall WA, Vallera DA (2006) Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus 20(4):E23. doi:10.3171/foc. 2006.20.4.15
27. Hall WA (2009) Convection-enhanced delivery: neurosurgical issues. Curr Drug Targets 10(2):126-130
28. Hall WA, Rustamzadeh E, Asher AL (2003) Convectionenhanced delivery in clinical trials. Neurosurg Focus 14(2):e2
29. Vogelbaum MA (2005) Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 73(1):57-69. doi:10.1007/s11060-004-2243-8 (Pubitemid 40823269)
30. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61(5):1031-1037; discussion 1037-1038. doi:10.1227/01.neu.0000303199.77370.9e 00006123-200711000-00017 [pii]
31. Vogelbaum MA (2007) Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol 83(1):97-109. doi:10.1007/s11060-006-9308-9 (Pubitemid 46647172)
32. Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA (2011) Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg 114(6):1662-1671. doi:10.3171/2010.11. JNS101214
33. Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, Vallera DA (2009) Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific liganddirected toxin, DTEGF13 and convection enhanced delivery. J Neurooncol 95(3):331-342. doi:10.1007/s11060-009-9932-2
34. Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 94(8):597-606 (Pubitemid 34498647)
35. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138(1):51-62. doi:10.1016/j.cell.2009.04.030
36. Rustamzadeh E, Low WC, Vallera DA, Hall WA (2003) Immunotoxin therapy for CNS tumor. J Neurooncol 64(1-2):101-116 (Pubitemid 36992465)
37. Rustamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA (2003) Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 65(1):63-75 (Pubitemid 37441314)
38. Koo JS, Kim SH (2011) EGFR and HER-2 status of non-small cell lung cancer brain metastasis and corresponding primary tumor. Neoplasma 58(1):27-34
39. Almasi CE, Christensen IJ, Hoyer-Hansen G, Dano K, Pappot H, Dienemann H, Muley T (2011) Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis. Lung Cancer 74(3):510-515. doi:10.1016/j.lungcan. 2011.05.008
40. Kroll RA, Neuwelt EA (1998) Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42(5):1083-1099; Discussion:1099-1100
41. Olson JJ, Zhang Z, Dillehay D, Stubbs J (2008) Assessment of a balloon-tipped catheter modified for intracerebral convectionenhanced delivery. J Neurooncol 89(2):159-168. doi:10.1007/s11060-008-9612-7
42. Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C (2007) Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60(2 Suppl 1):ONS89-98; discussion ONS98-89. doi:10.1227/01. NEU. 0000249256.09289.5F
43. Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR, Castro MG, Hall WA, Ohlfest JR (2007) Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg 107(3):568-577. doi:10.3171/JNS-07/09/0568 (Pubitemid 47451041)
44. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS (2004) Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 68(1):1-9 (Pubitemid 39137344)
45. Morrison PF, Chen MY, Chadwick RS, Lonser RR, Oldfield EH (1999) Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol 277(4 Pt 2):R1218-1229 (Pubitemid 29525980)
46. Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD, Gupta N (2010) A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol 96(2):151-159. doi:10.1007/s11060-009-9954-9
47. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD (2007) Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg 107(3):610-616. doi:10.3171/JNS-07/09/0610 (Pubitemid 47451046)
48. Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA (2009) Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 101(7):1114-1123. doi:10.1038/sj.bjc.6605297